EMCURE PHARMACEUTICALS
Quarterly Results Analysis [Jun2025]
EMCURE PHARMACEUTICALS Quarterly Results
Consolidated | Jun2025 UnAudited |
Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,101 Cr | ₹2,116 Cr | ₹1,963 Cr | ₹2,002 Cr | ₹1,815 Cr | ₹1,771 Cr | ₹1,668 Cr | ₹1,663 Cr |
Expenses | ₹1,684 Cr | ₹1,714 Cr | ₹1,608 Cr | ₹1,621 Cr | ₹1,478 Cr | ₹1,461 Cr | ₹1,361 Cr | ₹1,334 Cr |
Operating Income | ₹417 Cr | ₹402 Cr | ₹355 Cr | ₹381 Cr | ₹337 Cr | ₹311 Cr | ₹307 Cr | ₹329 Cr |
Other Income | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹36 Cr | ₹23 Cr | ₹12 Cr | ₹16 Cr | ₹1 Cr |
Interest | ₹27 Cr | ₹39 Cr | ₹32 Cr | ₹46 Cr | ₹59 Cr | ₹65 Cr | ₹61 Cr | ₹59 Cr |
Depreciation | ₹99 Cr | ₹97 Cr | ₹97 Cr | ₹97 Cr | ₹94 Cr | ₹91 Cr | ₹84 Cr | ₹70 Cr |
Profit Before Tax | ₹291 Cr | ₹261 Cr | ₹230 Cr | ₹273 Cr | ₹207 Cr | ₹167 Cr | ₹171 Cr | ₹198 Cr |
Profit After Tax | ₹215 Cr | ₹197 Cr | ₹156 Cr | ₹202 Cr | ₹153 Cr | ₹121 Cr | ₹120 Cr | ₹146 Cr |
EPS | ₹10.92 | ₹9.97 | ₹8.11 | ₹10.29 | ₹7.95 | ₹6.36 | ₹6.27 | ₹7.69 |
Industry Peers & Returns | 1W | 1M | 1Y |
EMCURE PHARMACEUTICALS | -2.5% | 0.6% | -8.5% |
SUN PHARMACEUTICAL INDUSTRIES | -0.3% | 3.2% | -13% |
DIVIS LABORATORIES | 7.2% | 8.6% | 6.8% |
CIPLA | 3% | 0.7% | -2.6% |
TORRENT PHARMACEUTICALS | -0.5% | NA | 0.6% |
DR REDDYS LABORATORIES | -1.1% | -5.3% | -6.3% |
MANKIND PHARMA | -1.4% | -5.3% | -12.8% |
ZYDUS LIFESCIENCES | -1.9% | -5.7% | -8.1% |
LUPIN | -0.9% | -5.2% | -12.9% |
EMCURE PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -0.74 % |
Y-o-Y | 15.72 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Jun2025 | ₹2,101 Cr | -0.74 | |
Mar2025 | ₹2,116 Cr | 7.83 | |
Dec2024 | ₹1,963 Cr | -1.97 | |
Sep2024 | ₹2,002 Cr | 10.29 | |
Jun2024 | ₹1,815 Cr | 2.47 | |
Mar2024 | ₹1,771 Cr | 6.22 | |
Dec2023 | ₹1,668 Cr | 0.27 | |
Sep2023 | ₹1,663 Cr | - |
EMCURE PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 3.57 % |
Y-o-Y | 23.79 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Jun2025 | ₹417 Cr | 3.57 | |
Mar2025 | ₹402 Cr | 13.48 | |
Dec2024 | ₹355 Cr | -6.90 | |
Sep2024 | ₹381 Cr | 13.13 | |
Jun2024 | ₹337 Cr | 8.37 | |
Mar2024 | ₹311 Cr | 1.22 | |
Dec2023 | ₹307 Cr | -6.72 | |
Sep2023 | ₹329 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 4.37 % |
Y-o-Y | 6.95 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Jun2025 | 19.84% | 4.37 | |
Mar2025 | 19.01% | 5.20 | |
Dec2024 | 18.07% | -4.99 | |
Sep2024 | 19.02% | 2.53 | |
Jun2024 | 18.55% | 5.76 | |
Mar2024 | 17.54% | -4.73 | |
Dec2023 | 18.41% | -6.97 | |
Sep2023 | 19.79% | - |
EMCURE PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 8.90 % |
Y-o-Y | 40.76 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Jun2025 | ₹215 Cr | 8.90 | |
Mar2025 | ₹197 Cr | 26.36 | |
Dec2024 | ₹156 Cr | -22.55 | |
Sep2024 | ₹202 Cr | 32.09 | |
Jun2024 | ₹153 Cr | 26.09 | |
Mar2024 | ₹121 Cr | 1.05 | |
Dec2023 | ₹120 Cr | -17.88 | |
Sep2023 | ₹146 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 9.76 % |
Y-o-Y | 21.64 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Jun2025 | 10.23 % | 9.76 | |
Mar2025 | 9.32 % | 17.23 | |
Dec2024 | 7.95 % | -21.05 | |
Sep2024 | 10.07 % | 19.74 | |
Jun2024 | 8.41 % | 23.13 | |
Mar2024 | 6.83 % | -4.87 | |
Dec2023 | 7.18 % | -18.13 | |
Sep2023 | 8.77 % | - |
EMCURE PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 9.53 % |
Y-o-Y | 37.36 % |
Quarters | EPS | % Change | |
---|---|---|---|
Jun2025 | ₹10.92 | 9.53 | |
Mar2025 | ₹9.97 | 22.93 | |
Dec2024 | ₹8.11 | -21.19 | |
Sep2024 | ₹10.29 | 29.43 | |
Jun2024 | ₹7.95 | 25.00 | |
Mar2024 | ₹6.36 | 1.44 | |
Dec2023 | ₹6.27 | -18.47 | |
Sep2023 | ₹7.69 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD